Marques Irene, Severo Milton, Pinto António Gomes, Fonseca Cândida, Carvalho Henrique Cyrne
Serviço de Medicina Interna, Centro Hospitalar Universitário de Santo António (CHUdSA), Unidade Local de Saúde de Santo António, 4099-001 Porto, Portugal.
Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), 4050-313 Porto, Portugal.
J Clin Med. 2025 Jul 17;14(14):5079. doi: 10.3390/jcm14145079.
: We aimed to identify the factors associated with clinically important changes in quality of life (QoL) of real-world heart failure (HF) patients. : This is a single-centre, prospective cohort study including 419 patients at an HF clinic between January 2013 and February 2020. QoL was assessed regularly using Minnesota Living with Heart Failure Questionnaire (MLHFQ). We used five nested linear mixed-effects models to account for QoL measurements between patients and within-patient. Models were adjusted for time, sociodemographic factors, comorbidities, self-care adherence, and HF severity factors. : Median age was 78 years, 54.4% of patients were female, and 49.6% had left ventricle ejection fraction ≥ 50%. At baseline, 62.5% of patients were New York Heart Association (NYHA) class II. Median N-terminal-pro-B type natriuretic peptide level was 1454 pg/mL. Mean MLHFQ total score at baseline was 25 points (95%CI: 22.97-27.60). Having an implanted cardiac resynchronization therapy-pacemaker (CRT-P) was associated with moderate to large improvement in QoL (-13.55 points, 95%CI: -22.45--4.65). NYHA class II and estimated glomerular filtration rate < 30 mL/min/1.73 m were associated with small to moderate QoL deterioration (9.74 points, 95%CI: 6.74-12.75 and 5.82 points, 95%CI: 1.17-10.47, respectively). NYHA classes III or IV and a recent HF hospitalization were associated with large to very large QoL deterioration (28.39 points, 95%CI: 23.82-32.96; 60.59 points, 95%CI: 34.46-86.72; and 26.91 points, 95%CI: 21.80-32.03, respectively). : CRT-P implantation, NYHA class and HF hospitalization are associated with the most clinically important QoL changes.
我们旨在确定与现实世界中心力衰竭(HF)患者生活质量(QoL)发生具有临床重要意义变化相关的因素。这是一项单中心前瞻性队列研究,纳入了2013年1月至2020年2月期间在一家HF诊所的419例患者。使用明尼苏达心力衰竭生活问卷(MLHFQ)定期评估QoL。我们使用了五个嵌套的线性混合效应模型来考虑患者之间以及患者内部QoL的测量值。模型针对时间、社会人口学因素、合并症、自我护理依从性和HF严重程度因素进行了调整。中位年龄为78岁,54.4%的患者为女性,49.6%的患者左心室射血分数≥50%。在基线时,62.5%的患者为纽约心脏协会(NYHA)II级。N末端B型利钠肽原水平的中位数为1454 pg/mL。基线时MLHFQ总分的平均值为25分(95%CI:22.97 - 27.60)。植入心脏再同步治疗起搏器(CRT - P)与QoL的中度至大幅改善相关(-13.55分,95%CI:-22.45 - -4.65)。NYHA II级和估计肾小球滤过率<30 mL/min/1.73 m²与QoL的轻度至中度恶化相关(分别为9.74分,95%CI:6.74 - 12.75和5.82分,95%CI:1.17 - 10.47)。NYHA III级或IV级以及近期HF住院与QoL的大幅至非常大幅恶化相关(分别为28.39分,95%CI:23.82 - 32.96;60.59分,95%CI:34.46 - 86.72;以及26.91分,95%CI:21.80 - 32.03)。CRT - P植入、NYHA分级和HF住院与临床上最重要的QoL变化相关。